Unique ID issued by UMIN | UMIN000003528 |
---|---|
Receipt number | R000004281 |
Scientific Title | The efficacy and safety of Kampo (Japanese herbal) medicine, bofutsushosan, on matabolic syndrome -a randomized, double-blind, placebo-controlled trial- |
Date of disclosure of the study information | 2010/04/24 |
Last modified on | 2013/04/25 18:46:19 |
The efficacy and safety of Kampo (Japanese herbal) medicine, bofutsushosan, on matabolic syndrome -a randomized, double-blind, placebo-controlled trial-
The efficacy and safety of bofutsushosan on matabolic syndrome
The efficacy and safety of Kampo (Japanese herbal) medicine, bofutsushosan, on matabolic syndrome -a randomized, double-blind, placebo-controlled trial-
The efficacy and safety of bofutsushosan on matabolic syndrome
Japan |
metabolic syndrome
Medicine in general | Cardiology | Endocrinology and Metabolism |
Others
NO
To examine whether bofutsushosan is useful for metabolic syndrome and which condition affects its usefulness from the viewpoint of Kampo medicine
Safety,Efficacy
Confirmatory
Pragmatic
Not applicable
body weight after 6-month administration
abdominal circumference, blood pressure, HDL, LDL, TG, HbA1c, FBS, HOMA-IR, hs-CRP, CAVI, S100A12, adiponectin, TNF-alfa, and SF-36 after 6-month administration and adverse events during the test period
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
NO
NO
Institution is not considered as adjustment factor.
YES
Central registration
2
Treatment
Medicine |
27 extract tablets of bofutsushosan manufactured by Kracie Pharmaceutical Ltd. per day, in 3 divided doses before or between meals, during 6 months
27 placebo tablets per day, in 3 divided doses before or between meals, during 6 months
20 | years-old | <= |
Not applicable |
Male and Female
Both A and B are required
A: abdominal circumference: 85 cm or over in men and 90 cm or over in women
B: one or more requirements below shold be met
1.[TG: 150mg/dl or over] and/or [HDL 40mg/dl or over]
2.[systolic blood pressure: 130mmHg or over] and/or [diastorlic blood pressure: 85mmHg or over]
3.fasting blood glucose: 110mg/dl or over
1.those who are taking Kampo drugs
2.those who have taken Kampo drugs in the past 4 weeks
3.those who need the treatment by conventional medicine
4.those who present significant liver or renal dysfunction
5.those who are taking the drugs affecting abdominal circumference or body weight
6.those who are taking antihyperlipidemic agents, antihypertensive agents, or antihyperglycemic agents
7.those with malignancy or heart failure which affects their general condition
8.those judged unsuitable for the trial by physician-in-charge
180
1st name | |
Middle name | |
Last name | Hiroshi Odaguchi |
Oriental Medicine Research Center, Kitasato University
Center for Evidence-Based Medicine
5-9-1, Shirokane, Minatoku, Tokyo
03-3444-6161
1st name | |
Middle name | |
Last name | Hiroshi Odaguchi |
Oriental Medicine Research Center, Kitasato University
Center for Evidence-Based Medicine
5-9-1, Shirokane, Minatoku, Tokyo
03-3444-6161
Oriental Medicine Research Center, Kitasato University
Ministry of Health, Labour and Welfare
NO
北里大学東洋医学総合研究所
2010 | Year | 04 | Month | 24 | Day |
Unpublished
Completed
2009 | Year | 12 | Month | 19 | Day |
2010 | Year | 03 | Month | 01 | Day |
2013 | Year | 03 | Month | 31 | Day |
2013 | Year | 06 | Month | 15 | Day |
2013 | Year | 07 | Month | 15 | Day |
2013 | Year | 10 | Month | 31 | Day |
2010 | Year | 04 | Month | 24 | Day |
2013 | Year | 04 | Month | 25 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004281